Pharmaceuticals
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval inChina will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ...
2022-11-17 08:10
5010
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...
2022-11-16 21:00
5750
MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System
MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VA...
2022-11-16 19:55
3550
YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent to European Union GMP
GAITHERSBURG, Maryland, Nov. 16, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics, today announced that...
2022-11-16 08:50
3181
Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA
--Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food and Drug Administration (FDA) to conduct a Phase Ib study in patients with monkeypox virus disease --Preclinical studies show that ASC10-A, active metabolite of double prodrug ASC10, has potent ant...
2022-11-16 08:10
4045
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2022-11-15 08:00
4841
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy
-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients inChina -- China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country -- Nefe...
2022-11-15 08:00
5027
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) an...
2022-11-14 20:06
3805
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
* Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US andCanada, and preparation for market availability * Shareholder commitment to TauRx represen...
2022-11-14 15:00
2318
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
ROCKVILLE,M.D. and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2022-11-14 08:00
4595
Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that DrChristian Behrenbruch,...
2022-11-11 20:00
6655
Winning the Fight Against Neuropathy in Diabetic Patients
P&G Health and medical experts share clinical guidance in the diagnosis and treatment of nerve damage among diabetic patients MANILA, Philippines, Nov. 11, 2022 /PRNewswire/ -- Ahead of World Diabetes Day 2022, P&G Health, brought together globally renowned multidisciplinary medical experts with...
2022-11-11 17:44
4327
LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY
TAIPEI, Taiwan, Nov. 11, 2022 /PRNewswire/ -- Lotus Pharmaceutical (1795: TT),
a multinational pharmaceutical company, today reported its financial results
for the third quarter ended30 September 2022.
2022-11-11 17:00
5019
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
MIAMI and PERTH, Australia, Nov. 11, 2022 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio. Today, Bridgewest Group has announced the signing of a definitive agree...
2022-11-11 10:07
4533
Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Nov. 11, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented...
2022-11-11 08:00
4484
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer, to...
2022-11-10 22:30
3435
Novo Nordisk earns the Best Place to Work Certification in Pakistan for 2022
ISLAMABAD, Nov. 10, 2022 /PRNewswire/ -- Novo Nordisk been officially recognized as one of the Best Places to Work inPakistan and Best Place to Work for Women recognizing the company's achievements in promoting continuous learning at work and in fostering a high-performing workplace culture. Duri...
2022-11-10 21:56
2926
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
LONDON and HONG KONG, Nov. 10, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter endedSeptember 30, 2022. Third Quarter 2022 and Rec...
2022-11-10 21:30
3798
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ --...
2022-11-09 23:32
3314
Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update
SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management ...
2022-11-09 21:09
4094
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36
Qunabox Group Opens '99 Quna Festival,' Debuting Consumer-Facing Physical AI Entertainment
[Picked up by 251 media titles]
2026-09-09 11:01
